Proportional Open Ventilation (POV) Device and Its Efficacy in Managing Acute Respiratory Failure in COVID-19 Patients

NAUnknownINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

August 28, 2020

Primary Completion Date

October 31, 2020

Study Completion Date

October 31, 2020

Conditions
Acute Respiratory FailureCovid19
Interventions
DEVICE

Life2000® Ventilator

"POV support (Life2000) will be administered in six (6) to ten (ten) enrolled subjects based on clinical protocol flowchart (Appendix C). Specifically, if it is determined that a COVID-19 subject who would currently be considered for HFNC under current standard of treatment, will be eligible for POV treatment.~The prescribed therapy regimen, including duration of therapy will be documented and COVID-19 patients who fail therapy and require IMV will be recorded."

Trial Locations (1)

55425

RECRUITING

Park Nicolette, Bloomington

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Hill-Rom

INDUSTRY